Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.66 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435751 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL6648331 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL5598310 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL5429914 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL3073495 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL10535915 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL24073266 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| N-(Decanoyl)Hexamethyleneimine SCHEMBL6012122 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL10481691 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL5433045 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736853-A2 | DEGRADANT COMPOUND IN A MEDICAMENT | Visus Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727533-A2 | SYNTHESIS OF 2-(CARBAMOYLOXY)-N,N,N-TRIMETHYLETHAN-1-AMINIUM SALTS | Visus Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4236932-B1 | DEGRADANT COMPOUND IN A MEDICAMENT | VISUS THERAPEUTICS INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20260000634-A1 | CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS | HERCULES CAPITAL, INC., AS AGENT | 2026-01-01 | — | — | US | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-12268662-B2 | Formulations comprising carbachol and brimonidine to enhance anti- presbyopia effects | VISUS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2024259258-A2 | SYNTHESIS OF 2-(CARBAMOYLOXY)-N,N,N-TRIMETHYLETHAN-1-AMINIUM SALTS | VISUS THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4429652-A1 | CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS | Visus Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240100009-A1 | CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS | HERCULES CAPITAL, INC., AS AGENT | 2024-03-28 | — | — | US | disclosed |
| US-20240100046-A1 | DEGRADANT COMPOUND IN A MEDICAMENT | VISUS THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-108273065-B | Ophthalmic composition | 药品配送方案有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-106074362-A | The ophthalmic preparation of Squalamine | OHR制药股份有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-102725305-B | Melanocortin-1 receptor-specific cyclic peptides | 帕拉丁科技公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-103533962-A | Ophthalmic composition | DRUG DELIVERY SOLUTIONS LTD | 2014-01-22 | — | — | CN | disclosed |
| CN-103209683-A | Ophthalmic formulation of squalamine | OHR PHARMACEUTICAL INC | 2013-07-17 | — | — | CN | disclosed |
| EP-1903074-B1 | RESIN COMPOSITION | ZEON CORP (JP) | 2009-10-14 | — | — | EP | disclosed |
| EP-1903074-A1 | RESIN COMPOSITION | ZEON CORPORATION (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-4837026-A | Transdermal and systemic preparation and method | THERAPEUTIC PATCH RESEARCH N.V. | 1989-06-06 | — | — | US | disclosed |
| EP-0240554-A1 | TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD | RAJADHYAKSHA, Vithal J. (US) | 1987-10-14 | — | — | EP | disclosed |
| WO-1987001935-A1 | TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD | RAJADHYAKSHA VITHAL J | 1987-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100046-A1 | DEGRADANT COMPOUND IN A MEDICAMENT | CHRM2, CHRM5, CHRM3 | L3MBTL1 4220/4885MEN1 359/4885KMT2A 2872/4885 |
| US-20260000634-A1 | CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS | CHRM2, CHRM4, CHRM3 | L3MBTL1 4431/4885MEN1 898/4885KMT2A 2077/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | L3MBTL1 4862/4885MEN1 4840/4885KMT2A 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.